These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

802 related articles for article (PubMed ID: 8044790)

  • 41. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
    Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of etoposide in combination with cyclosporin for purging multidrug-resistant leukemic cells from bone marrow in a mouse model.
    Kühl JS; Sikic BI; Blume KG; Chao NJ
    Exp Hematol; 1992 Oct; 20(9):1048-54. PubMed ID: 1468539
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
    Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma.
    Teicher BA; Alvarez E; Liu P; Lu K; Menon K; Dempsey J; Schultz RM
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):55-62. PubMed ID: 10598556
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
    Winkelhake JL; Stampfl S; Zimmerman RJ
    Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Response of ovarian cancer to combined cytotoxic agents in the subrenal capsule assay: Part I.
    Mäenpää J; Kangas L; Grönroos M
    Obstet Gynecol; 1985 Nov; 66(5):708-13. PubMed ID: 3932908
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Combination chemotherapy of HO-221, a derivative of benzoylphenylurea with various anticancer agents against human cancer xenografts in nude mice].
    Fujita F; Fujita M; Inaba H; Sugimoto T; Okuyama Y; Taguchi T
    Gan To Kagaku Ryoho; 1991 Oct; 18(13):2263-70. PubMed ID: 1929447
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antileukemic effects of recombinant human tumor necrosis factor alpha (rh-TNF alpha) with cyclophosphamide or methotrexate on leukemia L1210 and leukemia P388 in mice.
    Warzocha K; Robak T
    Acta Haematol Pol; 1992; 23(1):55-62. PubMed ID: 1615753
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Combined effect of PT-050 (recombinant human TNF) and antitumor drugs on syngeneic murine tumors].
    Nakata K; Yoshida H; Kashimoto S; Sohmura Y; Nakamura S; Taguchi T
    Gan To Kagaku Ryoho; 1986 Oct; 13(11):3186-93. PubMed ID: 3096217
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo.
    Krosnick JA; Mulé JJ; McIntosh JK; Rosenberg SA
    Cancer Res; 1989 Jul; 49(14):3729-33. PubMed ID: 2736513
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antitumor activity and hematotoxicity of a new, substituted dihydrobenzoxazine, FK973, in mice.
    Shimomura K; Manda T; Mukumoto S; Masuda K; Nakamura T; Mizota T; Matsumoto S; Nishigaki F; Oku T; Mori J
    Cancer Res; 1988 Mar; 48(5):1166-72. PubMed ID: 3342397
    [TBL] [Abstract][Full Text] [Related]  

  • 52. L-histidinol: preclinical therapeutic studies in combination with antitumor agents and pharmacokinetic studies in mice.
    Zaharko D; Plowman J; Waud W; Dykes D; Malspeis L
    Cancer Res; 1992 Jul; 52(13):3604-9. PubMed ID: 1617631
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preclinical studies on NSC290205 aza-steroid alkylator activity in combination with adriamycin against lymphoid leukaemia.
    Trafalis DT; Tsavdaridis D; Camoutsis C; Karayiani V; Mourelatos D; Dalezis P; Athanassiou A; Pangalis GA; Papageorgiou A
    Br J Haematol; 2005 Feb; 128(3):343-50. PubMed ID: 15667536
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
    Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide.
    Burres NS; Clement JJ
    Cancer Res; 1989 Jun; 49(11):2935-40. PubMed ID: 2720652
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model.
    Plum SM; Hanson AD; Volker KM; Vu HA; Sim BK; Fogler WE; Fortier AH
    Clin Cancer Res; 2003 Oct; 9(12):4619-26. PubMed ID: 14555538
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
    Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
    Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination effect of recombinant human interleukin 1 alpha with antitumor drugs on syngeneic tumors in mice.
    Nakamura S; Kashimoto S; Kajikawa F; Nakata K
    Cancer Res; 1991 Jan; 51(1):215-21. PubMed ID: 1899039
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antitumor activity of 7-N-[[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]]-mitomycin C.
    Morimoto M; Ashizawa T; Ohno H; Azuma M; Kobayashi E; Okabe M; Gomi K; Kono M; Saitoh Y; Kanda Y
    Cancer Res; 1991 Jan; 51(1):110-5. PubMed ID: 1988076
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Circumvention of drug resistance of P388/R cells by the combination of adriamycin and mitoxantrone with hyperthermia (42 degrees C).
    Juvekar AS; Chitnis MP
    Neoplasma; 1991; 38(2):207-11. PubMed ID: 2041579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.